Updates in the Treatment of Renal Cell Carcinoma: Highlights from IKCS and ESMO 2022

Brian Rini, MD, presents updated data from the CLEAR trial of lenvatinib plus pembrolizumab versus sunitinib in frontline advanced renal cell carcinoma.

Hans Hammers, MD, shares whether the updated CLEAR trial data would make him consider an IO-TKI regimen for patients with advanced RCC over an IO-IO regimen.

Moshe Ornstein, MD, explains which patients with RCC he observes for progression prior to systemic therapy.

The panel discusses the potential impact of updated data from the CLEAR trial on the treatment of patients with advanced RCC in clinical practice.

Experts summarize their most common frontline treatment approaches to advanced RCC.

The panel discusses which patients they would consider switching between immunotherapy combination treatments.

Best approaches to dosing and dose-reduction of TKI agents in the treatment of advanced RCC.

The doctors review data from the COSMIC-313 trial investigating a frontline triplet therapy for advanced RCC.

The panel continues their discussion of investigational triplet therapies in frontline RCC treatment.

Tian Zhang, MD, explains whether recent data from ESMO 2022 has changed their approach to adjuvant immune therapy in advanced RCC.

The panel shares how they would treat a patient with advanced RCC after disease progression on adjuvant pembrolizumab.

The panel wraps up their discussion with a review of how they would approach treating frontline non-clear cell RCC.

A panel of experts discuss the updated results of the phase 3 CLEAR trial presented at the 2022 International Kidney Cancer Symposium.